UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2022
Ocuphire Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-34079
|
|
11-3516358
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
37000 Grand River Avenue, Suite 120
Farmington Hills,
MI
|
|
48335
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (248) 681-9815
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value
|
OCUP
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
On January 5, 2022, Ocuphire Pharma, Inc. (the “Company”) issued a press release regarding the Company’s fourth quarter 2021 activity, cash balance
and upcoming events. The press release also notes the Company’s total common stock outstanding as of December 31, 2021, which stood at 18,845,828 shares. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K
(this “Report”).
Also on January 5, 2022, the Company posted an updated corporate presentation to its website at https://ir.ocuphire.com/presentations, which the
Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.
The information in this Report, including Exhibits 99.1 and 99.2 hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth
by specific reference in such a filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
This Report and the exhibits hereto contain forward-looking statements within the meaning of the federal securities laws. These forward looking
statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in the exhibits hereto and in the other reports of the Company filed with the
Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
Number
|
|
Exhibit Description
|
| |
|
|
|
|
|
Press Release, dated January 5, 2022
|
|
|
|
Corporate Presentation, dated January 5, 2022
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| |
OCUPHIRE PHARMA, INC.
|
| |
|
|
| |
By:
|
|
| |
|
Mina Sooch
|
| |
|
Chief Executive Officer
|
| |
|
|
|
Date: January 5, 2022
|
|
|